LIVE

LATEST

The Only Witness to the 'World's First AI Government Hack' Is the Company That Raised $61 Million to Say It Happened. The Report Has Since Been Removed.|China Blocked the Chips That Exist to Guarantee Demand for the Chips That Don't. The $295 Billion Plan Is a Bet on SMIC, and Nobody Has Verified SMIC Can Win It.|Three Labs. $2.6 Billion. One Argument. LLMs Can't Get to Intelligence. The Investors Funding All Three Bets Simultaneously Haven't Resolved Which Architecture Wins.|OpenAI Wants a $1 Trillion IPO Valuation. It Lost $1.22 for Every Revenue Dollar Last Quarter. The CFO Knows 2027 Works Better. So Does the Math.|AMD Is at $532. Its Biggest Customers Own Warrants That Vest When It Hits $600. Nobody Is Writing About It.|Cerebras Fixed Its Concentration Problem. It Replaced 86% UAE Dependency With 86% OpenAI Dependency. Now OpenAI Is Also Its Lender.|Cognition's Two Headline Numbers Both Need Asterisks. The Real Story Is More Interesting Than Either.|Every Headline Says 'Alibaba Stole Claude.' Anthropic's Letter to the Senate Says 'Operators Affiliated With Alibaba.' That Difference Is the Whole Story.|The Only Witness to the 'World's First AI Government Hack' Is the Company That Raised $61 Million to Say It Happened. The Report Has Since Been Removed.|China Blocked the Chips That Exist to Guarantee Demand for the Chips That Don't. The $295 Billion Plan Is a Bet on SMIC, and Nobody Has Verified SMIC Can Win It.|Three Labs. $2.6 Billion. One Argument. LLMs Can't Get to Intelligence. The Investors Funding All Three Bets Simultaneously Haven't Resolved Which Architecture Wins.|OpenAI Wants a $1 Trillion IPO Valuation. It Lost $1.22 for Every Revenue Dollar Last Quarter. The CFO Knows 2027 Works Better. So Does the Math.|AMD Is at $532. Its Biggest Customers Own Warrants That Vest When It Hits $600. Nobody Is Writing About It.|Cerebras Fixed Its Concentration Problem. It Replaced 86% UAE Dependency With 86% OpenAI Dependency. Now OpenAI Is Also Its Lender.|Cognition's Two Headline Numbers Both Need Asterisks. The Real Story Is More Interesting Than Either.|Every Headline Says 'Alibaba Stole Claude.' Anthropic's Letter to the Senate Says 'Operators Affiliated With Alibaba.' That Difference Is the Whole Story.|

All Finance Cybersecurity Biotech Sports Technology General

The Benchmark That Made GPT-Rosalind Famous Measures Bioinformatics. Drug Discovery Is a Different Problem.

GPT-Rosalind scored 0.751 on BixBench — a 0.201-point lead over Gemini 3.1 Pro — and launched with Amgen, Moderna, and Novo Nordisk as partners. Coverage treated this as the opening of AI drug discovery at scale. BixBench measures sequencing data processing, statistical analysis, and genomic interpretation — the computational work biologists do before drug discovery begins. No benchmark measuring actual drug discovery milestones (target identification, lead optimization, ADMET prediction) has been published for GPT-Rosalind. No fully AI-discovered drug has cleared Phase III anywhere. The four largest pharma companies by revenue — Pfizer, Roche, J&J, Merck — are not launch partners. And nobody disclosed what Amgen, Moderna, and Novo Nordisk actually agreed to.

Vera Flux·23h ago